Immunologic changes after house dust mite modified rush subcutaneous immunotherapy in allergic rhinitis children.

IF 1.6 Q3 ALLERGY

Asia Pacific Allergy Pub Date : 2022-01-17 eCollection Date: 2022-01-01 DOI:10.5415/apallergy.2022.12.e4

Tipyapa Rattanamanee, Putthapoom Lumjiaktase, Nanthisa Kemawichanura, Potjanee Kiewnga, Wanlapa Jotikasthira, Wiparat Manuyakorn

{"title":"Immunologic changes after house dust mite modified rush subcutaneous immunotherapy in allergic rhinitis children.","authors":"Tipyapa Rattanamanee, Putthapoom Lumjiaktase, Nanthisa Kemawichanura, Potjanee Kiewnga, Wanlapa Jotikasthira, Wiparat Manuyakorn","doi":"10.5415/apallergy.2022.12.e4","DOIUrl":null,"url":null,"abstract":"Background: House dust mites (HDM) are the major causative allergen for allergic rhinitis. The sole disease-modifying therapy for allergic rhinitis is allergen immunotherapy (AIT). Rush immunotherapy is the accelerated build-up schedules to reach the target maintenance dose.Objective: To evaluate the kinetic changes of peripheral blood CD4+CD25+FOXP3+ regulatory T cells (Treg) and serum cytokines in children undergoing 2-day modified rush HDM AIT.Methods: Children aged 5-15 years with allergic rhinitis were enrolled for a 2-day modified rush HDM AIT. Peripheral blood CD4+CD25+FOXP3+ Treg, serum interleukin (IL)-4, IL-13, interferon-γ, and IL-10 were measured at baseline, finishing rush, achieving maintenance dose, 6 months, and 12 months after reaching maintenance dose. Specific IgE (sIgE) to HDM was evaluated at baseline and 12 months after getting the maintenance dose. Rhinitis symptoms were assessed daily using a daily card.Results: A total of 12 children with a mean age of 13 years were enrolled. Rhinitis symptom-free days per month increased significantly after reaching the maintenance dose compared to baseline (from 9.5 days to 19.5 days, p = 0.002), and the maximum improvement was seen at 1 year. The levels of Treg were significantly increased at 6 months after maintenance dose compared to baseline level (6.27%±1.63% vs. 3.83%±1.80%, p < 0.001). After treatment, there were significantly decreased serum IL-13 at 1 year after maintenance but no significant changes in sIgE to HDM. The systemic reaction during AIT occurred 7 episodes from 119 shots (5.9%).Conclusion: Two-day modified rush HDM AIT provides acceptable systemic reactions and increases the number of CD4+CD25+FOXP3+ Treg in children.","PeriodicalId":8488,"journal":{"name":"Asia Pacific Allergy","volume":"12 1","pages":"e4"},"PeriodicalIF":1.6000,"publicationDate":"2022-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/9e/6f/apa-12-e4.PMC8819415.pdf","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Asia Pacific Allergy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5415/apallergy.2022.12.e4","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"ALLERGY","Score":null,"Total":0}

引用次数: 2

Abstract

Background: House dust mites (HDM) are the major causative allergen for allergic rhinitis. The sole disease-modifying therapy for allergic rhinitis is allergen immunotherapy (AIT). Rush immunotherapy is the accelerated build-up schedules to reach the target maintenance dose.

Objective: To evaluate the kinetic changes of peripheral blood CD4+CD25+FOXP3+ regulatory T cells (Treg) and serum cytokines in children undergoing 2-day modified rush HDM AIT.

Methods: Children aged 5-15 years with allergic rhinitis were enrolled for a 2-day modified rush HDM AIT. Peripheral blood CD4+CD25+FOXP3+ Treg, serum interleukin (IL)-4, IL-13, interferon-γ, and IL-10 were measured at baseline, finishing rush, achieving maintenance dose, 6 months, and 12 months after reaching maintenance dose. Specific IgE (sIgE) to HDM was evaluated at baseline and 12 months after getting the maintenance dose. Rhinitis symptoms were assessed daily using a daily card.

Results: A total of 12 children with a mean age of 13 years were enrolled. Rhinitis symptom-free days per month increased significantly after reaching the maintenance dose compared to baseline (from 9.5 days to 19.5 days, p = 0.002), and the maximum improvement was seen at 1 year. The levels of Treg were significantly increased at 6 months after maintenance dose compared to baseline level (6.27%±1.63% vs. 3.83%±1.80%, p < 0.001). After treatment, there were significantly decreased serum IL-13 at 1 year after maintenance but no significant changes in sIgE to HDM. The systemic reaction during AIT occurred 7 episodes from 119 shots (5.9%).

Conclusion: Two-day modified rush HDM AIT provides acceptable systemic reactions and increases the number of CD4+CD25+FOXP3+ Treg in children.

Abstract Image

查看原文本刊更多论文

儿童变应性鼻炎屋尘螨改良匆匆皮下免疫治疗后的免疫变化。

背景:室内尘螨(HDM)是过敏性鼻炎的主要致变原。变应性鼻炎唯一的疾病改善疗法是过敏原免疫疗法(AIT)。快速免疫疗法是加速累积时间表，以达到目标维持剂量。目的:评价2 d改良急急HDM AIT患儿外周血CD4+CD25+FOXP3+调节性T细胞(Treg)及血清细胞因子的动力学变化。方法:5-15岁的变应性鼻炎患儿参加为期2天的改良匆忙HDM AIT。测定外周血CD4+CD25+FOXP3+ Treg、血清白细胞介素(IL)-4、IL-13、干扰素-γ和IL-10在基线、冲刺结束、达到维持剂量、6个月和达到维持剂量后12个月的水平。在基线和获得维持剂量后12个月评估对HDM的特异性IgE (sIgE)。使用每日卡片评估鼻炎症状。结果:共纳入12名儿童，平均年龄13岁。与基线相比，达到维持剂量后每月鼻炎无症状天数显着增加(从9.5天增加到19.5天，p = 0.002)，并且在1年时看到最大的改善。与基线水平相比，维持剂量后6个月Treg水平显著升高(6.27%±1.63% vs. 3.83%±1.80%，p < 0.001)。治疗后，维持1年后血清IL-13明显降低，但sIgE与HDM无明显变化。119次注射中发生7次全身反应(5.9%)。结论:2天改良匆忙HDM AIT可提供可接受的全身反应，并可增加儿童CD4+CD25+FOXP3+ Treg的数量。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Asia Pacific Allergy ALLERGY-

CiteScore

2.50

自引率

5.90%

发文量

期刊介绍： Asia Pacific Allergy (AP Allergy) is the official journal of the Asia Pacific Association of Allergy, Asthma and Clinical Immunology (APAAACI). Although the primary aim of the journal is to promote communication between Asia Pacific scientists who are interested in allergy, asthma, and clinical immunology including immunodeficiency, the journal is intended to be available worldwide. To enable scientists and clinicians from emerging societies appreciate the scope and intent of the journal, early issues will contain more educational review material. For better communication and understanding, it will include rational concepts related to the diagnosis and management of asthma and other immunological conditions. Over time, the journal will increase the number of original research papers to become the foremost citation journal for allergy and clinical immunology information of the Asia Pacific in the future.